List view / Grid view
LifeArc, the UK medical research charity previously known as MRC Technology; The Centre for Drug Research and Development (CDRD); and the Defence Science and Technology Laboratory (Dstl), have announced a collaboration to identify antibacterial drug targets.
Scientists have given new superpowers to an antibiotic called vancomycin, an advance that could eliminate the threat of antibiotic-resistant infections.
New research provides insights into why infection with Zika virus after birth generally causes only mild symptoms, whereas devastating foetal malformations can develop when infection occurs during pregnancy.
Researchers develop bacteria-fighting wound dressing made with the help of crustaceans…
Pfizer has launched the Antimicrobial Testing Leadership and Surveillance (ATLAS) website, which is designed to provide physicians and the global health community with easy access to critical data on the efficacy of various antibiotic treatments and emerging resistance patterns across more than 60 countries.
Polyphor Ltd, a clinical stage, privately held Swiss specialty pharma company focused on the development of macrocycle drugs addressing antibiotic resistance and respiratory diseases, has completed a CHF 40 million private placement. Exisiting Polyphor investors contributed to 98% of the financing.
Daiichi Sankyo has entered into a new joint research agreement with the Drugs for Neglected Diseases initiative (DNDi) with regard to a new research program, the Hit-to-Lead Project, with the aim of developing drug treatments for two neglected tropical diseases, leishmaniasis and Chagas disease.
24 January 2017 | By
Author and Scientific Director Jean de Gunzburg, from Da Volterra, will present keynote speech at 19th annual Superbugs summit...
Experts at EUCAST have found that genetic methods cannot yet be used to test for susceptibility in a number of important bacterial species.
21 November 2016 | By Niamh Louise Marriott, Digital Content Producer
Researchers at the University of Oxford have been working with two major EU-funded projects to deliver a novel antibiotic programme for clinical development...
11 October 2016 | By Niamh Louise Marriott, Digital Content Producer
The European Society of Clinical Microbiology and Infectious Diseases (ESCMID) and the American Society for Microbiology (ASM) have just closed a joint conference in Vienna, which aimed to help researchers accelerate the development of new antimicrobials and to shed light on the challenges associated with antimicrobial resistance.
The discovery and development of novel drug candidates is a highly complex, time-consuming and expensive process. Pharmaceutical scientists and clinicians should, therefore, reevaluate and modify the existing standard platforms and increase their uptake of robust advanced technologies such as flow cytometry to overcome the bottlenecks in these processes...
27 June 2016 | By European Society of Clinical Microbiology and Infectious Diseases (ESCMID)
ESCMID and ASM are jointly organising a conference to help researchers accelerate the development of new antimicrobials for drug-resistant infections...
20 June 2016 | By Victoria White, Digital Content Producer
We recently caught up with Frank Pasqualone of Theravance Biopharma to find out about the latest study results for the company's antibiotic, Vibativ...
25 May 2016 | By Victoria White, Digital Content Producer
The findings may lead to new therapeutic strategies and suggest limitations to therapies designed to eliminate amyloid plaques from Alzheimer's patient's brains...
